Systemic EBV-Positive T-Cell Lymphoma of Childhood
NCI Definition: An aggressive and life-threatening, EBV-positive T-cell lymphoproliferative disorder affecting children. It is more prevalent in Taiwan and Japan. Clinically, it presents with acute onset of fever and generalized malaise, followed by hepatosplenomegaly and liver failure. Morphologically it is characterized by the presence of infiltrating T-lymphocytes which are usually small and erythrophagocytosis. Most patients have a fulminant clinical course. 
There are 2 clinical trials for systemic EBV-positive T-cell lymphoma of childhood, of which 2 are open and 0 are completed or closed. Of the trials that contain systemic EBV-positive T-cell lymphoma of childhood as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).
Lmp1/barf1/ebna1-specific cytotoxic t-lymphocytes, camrelizumab, and rivoceranib are the most common interventions in systemic EBV-positive T-cell lymphoma of childhood clinical trials.
Significant Genes in Systemic EBV-Positive T-Cell Lymphoma of Childhood
ALK is an inclusion eligibility criterion in 1 clinical trial for systemic EBV-positive T-cell lymphoma of childhood, of which 1 is open and 0 are closed. Of the trial that contains ALK status and systemic EBV-positive T-cell lymphoma of childhood as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.